Simulations Plus (SLP) AI-Driven Drug Design Collaboration Yields Positive Results

Simulations Plus, Inc. (NASDAQ:SLP) is one of the top 10 medical AI companies to buy according to analysts. On July 29, the company confirmed that its artificial intelligence-driven drug design collaboration with the Institute of Medical Biology of the Polish Academy of Sciences (IMB PAS) has yielded promising results.

Simulations Plus (SLP) AI-Driven Drug Design Collaboration Yields Positive Results

The positive results relate to the development of novel compounds targeting inflammation and immune responses. The results show that 70% of the 27 compounds designed using the ADMET Predictor software demonstrated significant inhibition of RORyT activity. The outcomes support the company’s algorithms and platform, which utilize machine learning and artificial intelligence to develop and optimize drugs for specific targets, providing clients with a first-to-invent advantage.

Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences have been collaborating on developing RORγ/RORγT ligands. These molecules impact gene expression related to inflammation and immune responses.

Simulations Plus, Inc. (NASDAQ:SLP) integrates AI and machine learning (ML) into its modeling and simulation software to enhance drug discovery and development. It leverages AI/ML to predict drug behavior in the body, optimize chemical compounds, and accelerate the overall drug development process.

While we acknowledge the potential of SLP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLP and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Farmland and Agriculture Stocks to Buy According to Billionaires and 10 Best Stocks to Buy Amid Gold Rally.

Disclosure: None. This article is originally published at Insider Monkey.